Clinical Trial ProgressThe company is on track to complete enrollment in the 114-patient Phase 3 TIGeR-PaC study, which is crucial for advancing its treatment for pancreatic cancer.
Revenue MilestoneRenovoCath realizes first revenues, marking a significant milestone for the company.
ValuationRNXT, with a current valuation, is considered undervalued and could be attractive.